Clinical implications of early caudate dysfunction in Parkinson’s disease

Jacopo Pasquini,1,2 Rory Durcan,3 Louise Wiblin,3 Morten Gersel Stokholm,4 Lynn Rochester,3,5 David James Brooks,3,4 David Burn,5,6 Nicola Pavese3,4

ABSTRACT
Objective Although not typical of Parkinson’s disease (PD), caudate dopaminergic dysfunction can occur in early stages of the disease. However, its frequency and longitudinal implications in large cohorts of recently diagnosed patients remain to be established. We investigated the occurrence of caudate dopaminergic dysfunction in the very early phases of PD (<2 years from diagnosis) using 123I-FP-CIT single photon emission CT and determined whether it was associated with the presence or subsequent development of cognitive impairment, depression, sleep and gait problems.

Methods Patients with PD and healthy controls were identified from the Parkinson’s Progression Markers Initiative (PPMI) database. We defined a clinically significant caudate dysfunction as 123I-FP-CIT binding <−2 SDs compared with the controls’ mean and categorised three groups accordingly (no reduction, unilateral reduction, bilateral reduction). All statistical analyses were adjusted for mean putamen binding.

Results At baseline, 51.6% of 397 patients had normal caudate dopamine transporter binding. 26.0% had unilateral caudate involvement, and 22.4% had bilaterally impaired caudate. Compared with those with a baseline normal caudate function, at the 4-year follow-up patients with a baseline bilateral caudate involvement showed a higher frequency of cognitive impairment (p<0.001) and depression (p<0.001), and worse cognitive (p<0.001), depression (<0.05) and gait (<0.01) ratings. Significant caudate involvement was observed in 83.9% of the population after 4 years (unilateral 22.5%, bilateral 61.4%).

Conclusions Early significant caudate dopaminergic denervation was found in half of the cases in the PPMI series. Baseline bilateral caudate involvement was associated with increased risk of developing cognitive impairment, depression and gait problems over the next 4 years.

INTRODUCTION
Caudate dopaminergic dysfunction is commonly seen in patients with established and advanced Parkinson’s disease (PD) and plays a role in the pathophysiology of parkinsonian symptoms such as cognitive impairment,1–7 depression,3 RELM sleep behaviour disorder (RBD)8 and gait problems.9 10 Conversely, both postmortem and in vivo imaging studies suggest that caudate function is preserved in the early stages of PD. In fact, dopaminergic neurons of the substantia nigra pars compacta (SNc) degenerate in a selective pattern, with earliest and most severe loss occurring in the ventral tier projecting to the posterior putamen and tail of caudate, followed by the dorsal tier projecting to the head of caudate nucleus, the globus pallidus and the neocortex.12 13 Neuroimaging studies using single photon emission CT (SPECT) and PET dopaminergic tracers14–16 confirm that the dopaminergic deficit within the striatum is unevenly distributed with a more severe involvement of the posterior putamen and a relative sparing of the head of caudate nucleus. This asymmetrical posterior-to-anterior gradient of dopaminergic dysfunction is present from early disease stages and does not change substantially with disease progression.17 18 However, the occurrence of caudate involvement in the early stages of the disease and the clinical implications of such early caudate dysfunction (ie, the current or subsequent manifestation of cognitive impairment, depression, RBD, gait problems) have not been fully investigated in large cohorts.

MATERIALS AND METHODS
Study design and participants
In this longitudinal study, we analysed clinical and neuropsychological data and N-ω-fluoropropyl-2β-carboxymethoxy-3β-[123I]iodophenyl-nortropane ([123I-FP-CIT]) SPECT data from a cohort of patients with early stage PD and healthy controls (HCs) recruited in the Parkinson’s Progression Markers Initiative (PPMI), an ongoing multicentre, longitudinal study aiming to identify biomarkers of PD progression. Patients with PD were required to have a clinical diagnosis for 2 years or less, be untreated and show evidence of striatal dopamine transporter (DAT) deficit on SPECT imaging (study protocol available at https://www.ppmi-info.org/study-design/research-documents-and-sops).19

We performed three main analyses: (1) we evaluated caudate [123I-FP-CIT] binding at baseline and follow-up in patients with PD and HCs. Patients with PD were categorised in three subgroups according to their baseline caudate binding compared with HCs (no reduction, unilateral reduction, bilateral reduction); (2) we assessed whether these three PD subgroups showed different baseline manifestations in terms of cognitive impairment, depression, RBD and gait problems; (3) we investigated whether the initial pattern of caudate dopaminergic dysfunction was able to predict worse outcomes and increased risk of developing cognitive, mood, sleep and gait problems at 4-year follow-up.
At the time of our analysis, we retrieved 405 patients with PD and 177 HCs whose baseline assessments, including SPECT scan, motor and non-motor scores were available in the PPMI database (http://www.ppmi-info.org/data). At 4-year follow-up, clinical assessments were available for 328 patients and SPECT imaging for 267. Four-year follow-up clinical assessments were available for 151 HCs; no follow-up SPECT imaging was provided for HCs in the PPMI.

123I-FP-CIT SPECT striatal specific binding ratios (SBRs) and demographics and clinical variables at baseline and 4-year follow-up of all the study participants were downloaded from the PPMI database on 15 May 2018.

Clinical evaluations
PD motor disability was assessed with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the Hoehn & Yahr (H&Y) scale. To assess differences in gait impairment between groups at baseline and 4-year follow-up, we calculated an index of gait severity by using the product of the patient’s self-reported walking and balance score (subitem 2.12, MDS-UPDRS part II) and the freezing score (2.13, MDS-UPDRS part II) (Maximum score =16). All scores were collected in the OFF state.

Scores of the following non-motor scales were also obtained: Montreal Cognitive Assessment (MoCA), the 15-item Geriatric Depression Scale (GDS) and RBDSQ. For each patient, one point was added to the MoCA unadjusted score of those who had 12 years of education or less, as indicated in the test original validation study20 and in the PPMI protocol. A GDS score ≥5 was considered diagnostic for dementia based on recommended criteria for dementia22 and as outlined in the PPMI protocol (see online supplementary material-section 1).

Study participants were allocated to one of three cognitive categories (normal cognition, mild cognitive impairment (MCI), dementia) based on recommended criteria for dementia22 and MCI23 and as outlined in the PPMI protocol (see online supplementary material-section 1).

Last, the final clinical diagnosis at 4-year follow-up based on clinical judgement of the investigator was recorded to determine if the patient’s diagnosis had changed compared with baseline.

Eight patients initially diagnosed as idiopathic PD were re-diagnosed as a form of atypical parkinsonism: four had their diagnosis switched to multiple system atrophy (MSA), three to dementia with Lewy bodies (DLB), one to corticobasal degeneration (CBD). These patients were excluded from the main analysis and their neuroimaging features analysed separately. Therefore, a total of 397 patients at baseline and 323 patients at follow-up were included in the main analysis.

123I-FP-CIT SPECT imaging protocol
A detailed description is provided in online supplementary material-section 2. Briefly, all subjects underwent 123I-FP-CIT SPECT scans during the screening visit and at follow-ups (patients with PD only) at their respective PPMI imaging centre, where standardised imaging protocols were used. Raw SPECT data were transferred back to the Institute for Neurodegenerative Disorders, New Haven, Connecticut, USA (PPMI Imaging Core), for processing and calculations of SBRs. On transfer to the PPMI imaging core, images were processed and normalised to standard Montreal Neurologic Institute (MNI) space so that all scans were in the same anatomical alignment. Next, the transaxial slice with the highest striatal binding was identified and the eight contiguous slices with highest striatal signal were then averaged to generate a single transaxial image. Regions of interest (ROI) were then placed to sample the left (area 240 mm²) and right caudate (area 244 mm²), the left (area 412 mm²) and right putamen (area 408 mm²) and the occipital cortex (reference tissue, area 4500 mm²).

Count densities for each region were extracted and used to calculate SBRs for each of the four striatal subregions. SBR = (target region/reference region) – 1.

SBRs of caudate and putamen of each participant were downloaded from the PPMI database. SBR measures were rounded to the first two decimals. Mean caudate DAT SBR≥SD (95% CI) in controls was 2.96±0.60 (2.88–3.06). The caudate signal was considered to be significantly abnormal in patients with PD if its level of 123I-FP-CIT binding fell two SD or more below the mean caudate binding of HCs at baseline (mean =2SDs=1.76). Three PD subgroups were then categorised as follows: those with no reduced 123I-FP-CIT binding in either caudate (PD-NC), those with reduced caudate binding in one caudate only (PD-UC) and those with bilaterally reduced caudate binding (PD-BC). Accordingly, we defined significant early caudate dysfunction a caudate 123I-FP-CIT binding <−2 SDs compared with the controls’ mean at the baseline SPECT acquisition.

Statistical analysis
Statistical interrogations were performed using the Statistical Package for the Social Sciences V.21 (SPSS 21). For descriptive analyses, means and SD were computed for continuous variables, and the χ² test was used for categorical variables. Data were assessed for a normal distribution using Kolmogorov-Smirnov test. MoCA, GDS and RBDSQ ratings were normally distributed, gait index scores showed a non-normal distribution.

At baseline, between-group differences were investigated using analysis of variance followed by a posthoc test with Bonferroni correction for normally distributed data. At follow-up, between-group differences of normally distributed variables were investigated through analysis of covariance followed by a posthoc test with Bonferroni correction, holding putamen, age and years of education as covariates where appropriate. Non-normally distributed data were explored through a Kruskal Wallis test followed by Mann-Whitney U tests, and p values were adjusted through a Bonferroni correction. All multiple comparisons for categorical data at baseline and follow-up were assessed through a χ² omnibus test followed by a standardised residuals analysis; p values were adjusted through a Bonferroni correction.

RESULTS
Baseline
The baseline analysis included 397 patients with PD (men/ women: 258/139, age: 61.7±9.7 years) and 177 HCs (men/ women: 116/61, age: 60.95±11.2 years). In 397 patients with PD, normal 123I-FP-CIT binding in either caudate nuclei (PD-NC) was noted in 51.6% (n=205) of patients, 26.0% (n=103) had reduced tracer binding in one caudate only (PD-UC) and 22.4% (n=89) had reduced tracer binding in both caudate nuclei (PD-BC) (figure 1A). No significant differences were found in the left/right distribution of the most affected caudate across the three PD subgroups. At baseline, all patients with a unilateral or bilateral caudate DAT reduction also had either a unilateral or bilateral putaminal reduction. More details about caudate and putamen involvement in individual patients are reported in online supplementary tables 1 and 2. Mean putamen SBR was significantly different across the three groups (F=90.003, p<0.001), with PD-BC significantly lower than the other two groups, and PD-UC significantly lower than PD-NC. However, the caudate/
putamen ratio, which provides an index of the posterior-to-anterior dopaminergic loss gradient, was not significantly different across the three groups. Age across the three PD subgroups and HCs was significantly different (F=3.657, p<0.05), with the PD-BC group being older (64.46±8.13 years) than HCs (60.95±11.20 years) and the other two PD subgroups (PD-NC: 60.98±10.16 years; PD-UC 60.63±9.76 years). In order to assess if there was a significant age-related decline in caudate DAT availability in our control cohort, we compared mean caudate SBRs in three subgroups of controls classified according to their baseline caudate specific binding ratios compared with healthy controls: no reduced 123I-FP-CIT binding in either caudate (PD-NC); 123I-FP-CIT caudate binding reduced below −2 SDs of the controls’ mean in one caudate only (PD-UC); 123I-FP-CIT caudate binding bilaterally reduced below −2 SDs of controls’ mean (PD-BC). The percentage of each subgroup in the PD cohort is displayed on the corresponding pie slice. PD, Parkinson’s disease.

There was no difference in self-reported gait impairment as measured by the gait index between the PD subgroups at baseline (H=3.924, p=0.141).

No significant correlations were found between mean caudate 123I-FP-CIT binding and cognitive, mood, RBD and gait impairment ratings at baseline.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline cohort demographics and characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Healthy controls</td>
<td>PD-NC</td>
</tr>
<tr>
<td>(n=177)</td>
<td>(n=205)</td>
</tr>
<tr>
<td><strong>Means±SD</strong></td>
<td><strong>Means±SD</strong></td>
</tr>
<tr>
<td>Age, years</td>
<td>60.95±11.20</td>
</tr>
<tr>
<td>Male/Female</td>
<td>116/61</td>
</tr>
<tr>
<td>Years of education</td>
<td>16.11±2.93</td>
</tr>
<tr>
<td>Duration of symptoms, years</td>
<td>1.53±0.20</td>
</tr>
<tr>
<td>Duration since diagnosis, years</td>
<td>0.14±0.40</td>
</tr>
<tr>
<td>Stage of disease (H&amp;Y)</td>
<td>1.46±0.50</td>
</tr>
<tr>
<td>MoCA examination</td>
<td>28.38±2.13</td>
</tr>
<tr>
<td>GDS score</td>
<td>1.30±2.14</td>
</tr>
<tr>
<td>GDS≥5</td>
<td>11 (6.2%)</td>
</tr>
<tr>
<td>RBDSQ</td>
<td>2.97±2.38</td>
</tr>
<tr>
<td>Gait Index –</td>
<td>0.32±0.80</td>
</tr>
</tbody>
</table>

Significant difference compared with healthy controls (*p<0.05).

GDS, Geriatric Depression Score; H&Y, Hoehn & Yahr scale; MDS-UPDRS, Movement Disorder Society Unified Parkinson’s Disease Rating Scale; MoCA, Montreal Cognitive Assessment; PD-BC, bilaterally reduced caudate binding; PD-NC, no reduced 123I-FP-CIT binding in either caudate; PD-UC, reduced 123I-FP-CIT binding in one caudate only; RBD, REM sleep behaviour disorder; RBDSQ, RBD Screening Questionnaire.

Figure 1 Pie chart representing the three groups of patients at baseline (A) and follow-up (B) classified according to their baseline caudate 123I-FP-CIT SPECT binding compared with healthy controls. Patients with Parkinson’s disease (baseline, n=397; follow-up, n=267) were categorised into three groups based on their baseline caudate specific binding ratios compared with healthy controls: no reduced 123I-FP-CIT binding in either caudate (PD-NC); 123I-FP-CIT caudate binding reduced below −2 SDs of the controls’ mean in one caudate only (PD-UC); 123I-FP-CIT caudate binding bilaterally reduced below −2 SDs of controls’ mean (PD-BC). The percentage of each subgroup in the PD cohort is displayed on the corresponding pie slice. PD, Parkinson’s disease.
Follow-up
Complete 4-year clinical assessments were available for 323 patients with PD and SPECT imaging for 267. Follow-up clinical data were available for 151 HCs. Given the smaller PD sample at follow-up, we compared the variables of gender, age, MoCA scores, GDS scores, RBDSQ scores and caudate SBRs between patients with and without available data at follow-up in order to check whether the follow-up cohort was representative of the baseline one. We did not find significant differences in these variables (online supplementary table 3).

We then compared ratings and frequencies of cognitive impairment, depressive features, RBD and gait problems at the 4-year follow-up among the three PD subgroups as classified at baseline according to their caudate SBRs. Since age and mean putamen SBR at baseline were significantly different across the three groups, we adjusted the comparisons of continuous scores for these variables. Finally, we analysed the occurrence of caudate dysfunction at follow-up and the conversion to atypical parkinsonism.

Cognitive impairment
At 4-year follow-up, MoCA scores were significantly different across PD subgroups: the PD-BC group had significantly lower MoCA scores compared with the PD-NC group (25.05±4.32 vs 26.93±3.06, p<0.001) and to the PD-UC group (25.05±4.32 vs 27.16±3.21, p<0.001) (figure 2A). After adjusting for age, years of education and baseline mean putamen SBR, these
Movement disorders

At 4-year follow-up, the PD-BC group showed significantly higher GDS scores compared with PD-NC after adjusting for age and mean putamen SBR (3.40±3.01 vs 2.25±2.63, p<0.05); no significant differences were observed between PD-BC and PD-UC groups and between PD-NC and PD-UC groups (figure 2B). Again, we conducted a general linear model (GLM) univariate analysis in order to test whether baseline caudate and putamen SBRs were associated with GDS scores; only caudate binding was significantly associated with GDS scores (B = −0.999, p< 0.05; putamen: B = 0.532, p = 0.544).

In terms of clinically significant depression, the PD-BC group had a higher frequency compared with the PD-NC group (29.6% vs 10.8%, χ² = 12.67, p < 0.001) but the frequency in the PD-UC group (one with MSA, one with CBD; their follow-up SPECT scans were not available). Baseline caudate mean SBR of these eight patients were significantly lower than the remaining patients (U = 722.5, p < 0.01); however, individual values overlapped with patients with idiopathic PD (data not shown).

DISCUSSION

In this longitudinal study, we analyse the occurrence of significant early caudate dopaminergic dysfunction, as defined by [123I-FP-CIT] SBR below −2 SDs compared with the controls’ mean, in the large PPMI cohort of patients with recently diagnosed PD. Furthermore, we studied the association between this early caudate DAT loss and the presence or subsequent development of cognitive impairment, depressive features, RBD and gait problems. Unlike previous studies, we provided a clinically viable method to define patients at risk of developing such symptoms. In fact, software for semiquantitative analysis of DAT-SPECT to estimate DAT availability in striatal subregions (ie, putamen and caudate) are now commercially available and already adopted in many Nuclear Medicine Units. The assessment of the occurrence of early caudate dysfunction as described in this paper can therefore be easily performed in clinical settings and could serve as a risk marker for worse disease progression.

In this study, we have used two SDs below the mean of the control population as the threshold to discriminate between normal or abnormal DAT availability of the caudate. DAT availability declines with age and our control population is slightly younger than the PD-BC group. Therefore, in order to assess if there was a significant age-related decline in caudate DAT availability in our control cohort, we compared mean caudate SBRs in three subgroups of controls classified according to their age (50–59, 60–69, ≥70). No significant differences were found in mean caudate DAT binding across these groups, suggesting that age-related decline of caudate binding in our cohort is minimal.

Previous neuroimaging and pathophysiological studies on striatal dopamine loss have shown uneven patterns of dopamine depletion in the basal ganglia. This has led to the concept of
a posterior-to-anterior gradient in early PD, with an asymmetric reduced striatal binding in the posterior putamen and relative preservation in the head of caudate. In this study, we observed baseline unilateral or bilateral caudate dopaminergic dysfunction, reflected by a reduced $^{123}$I-FP-CIT binding $<-2$ SDs compared with controls, in nearly half (48.4%) of this early, untreated PD cohort. This finding indicates that early caudate dopaminergic dysfunction is not uncommon in patients with PD at the onset of parkinsonian symptoms, as opposed to what was previously thought. Patients with unilateral and bilateral caudate involvement had a significantly reduced putamen $^{123}$I-FP-CIT binding compared with patients with no caudate dysfunction; however, the caudate/putamen ratio was not significantly different across PD subgroups, suggesting that the posterior-to-anterior gradient of dopaminergic loss is substantially preserved in all patients with PD.

At follow-up, the majority of patients (61.4%) showed significantly reduced DAT availability in both caudate nuclei, and 22.5% had significant reduction in one caudate only. Only 16.1% of patients retained normal caudate $^{123}$I-FP-CIT uptake bilaterally. These findings are in keeping with previous studies that have demonstrated similar caudate and putaminal involvement in patients with longer disease duration.17 18

Our results did not show a significant difference between the three PD subgroups, defined by the level of caudate dysfunction, on baseline assessments of cognition, mood or gait but only found a difference between PD subgroups with these measures at the 4-year follow-up. It is likely that baseline caudate dopaminergic deficits are not severe enough to cause marked impairment in either cognition, mood or gait but later predispose to such impairments, possibly in combination with other neurotransmitter systems dysfunction. Indeed, we interestingly found that this early, absolute significant reduction of caudate signal on $^{123}$I-FP-CIT SPECT compared with controls at the time of clinical diagnosis is associated with worse outcomes in regard to cognitive impairment, affective symptoms and gait problems at the 4-year follow-up.

Several SPECT studies using dopaminergic tracers have proposed a role for caudate dysfunction in cognitive impairment associated with PD.4 24 25 Furthermore, three studies have reported early caudate dopaminergic dysfunction as a predictor for future cognitive impairment.5 27 Our analysis showed that patients with PD with baseline bilateral caudate DAT binding reductions, but not unilateral reductions, are at greater risk of developing cognitive impairment and having lower MoCA scores regardless of their putamen DAT availability, age and years of education. Therefore, in comparison with the previously mentioned studies, we propose a practical approach that could be used in the clinical practice at time of diagnosis to determine which patients are at increased risk of developing cognitive problems in a near future.

Depression is highly prevalent in PD with rates as high as 40%.6 26 The aetiology of depression has been attributed to deficits, with varying degrees, in the dopaminergic, serotonergic, cholinergic and noradrenergic pathways.6 27 Several neuroimaging studies have shown an association between reduced DAT availability in the striatum and depressive symptoms.6 28 29 One study demonstrated a negative association between right caudate nucleus $^{123}$I-FP-CIT binding and the severity of depressive symptoms.8 Our study suggests that early bilateral caudate dopaminergic dysfunction is associated with an increased frequency of clinically significant depression and to worse depressive symptoms, regardless of age and mean putamen SBR. Therefore, our results concur with other studies and provide further evidence that depressive symptoms in patients with PD may be associated with dopaminergic denervation of the caudate. Again, we provided a clinical neuroimaging marker to determine which patients are at increased risk of developing worse depressive symptoms.

Our study also indicated that early bilateral caudate involvement may predispose to future development of self-reported gait impairment. A previous PET study has demonstrated substantial caudate nucleus dopaminergic denervation in patients with PD with gait difficulty which was predominantly associated with the right caudate.21

We did not identify significant differences in RBDSQ scores across the three groups of patients at baseline or at the 4-year follow-up. Although one study found lower DAT availability in the caudate nucleus of patients with PD with RBD compared with those without RBD,2 it is plausible that a more extensive network involving other neurotransmitter systems, such as the cholinergic pathways,32 are responsible for these symptoms. Furthermore, while the RBDSQ is a valid and widely used tool to assess RBD symptoms, only polysomnography, which was not performed in the PPMI study, could have provided a complete evaluation of RBD manifestations.

Eight patients initially diagnosed with idiopathic PD had their diagnosis switched to an atypical parkinsonism (MSA or CBD) or to DLB at the 4-year follow-up. These eight patients showed caudate mean SBR significantly lower than patients with idiopathic PD; however, individual values overlapped between the two groups. This is in line with previous studies that have demonstrated that in atypical parkinsonisms $^{123}$I-FP-CIT SPECT generally shows lower striatum uptake and different uptake patterns but is unable to accurately distinguish those syndromes from idiopathic PD.33 34

A number of limitations should be addressed. At follow up we studied a smaller sample size of 323 patients with clinical assessments and 267 patients with available SPECT scans; however, these are still relatively considerable numbers. In order to test whether the baseline and follow-up cohorts were similar, we verified that age, gender, MoCA scores, GDS scores, RBDSQ scores and caudate SBR at baseline were not significantly different between patients included and excluded from the follow-up analysis (online supplementary material 1). The clinical follow-up analysis only included the imaging variables of caudate and putamen DAT availability; the symptoms analysed might presumably be caused by extensive networks involving more than one neurotransmitter system; therefore, future multi-tracer studies may be necessary to confirm and further examine our results. Where appropriate, that is, for cognitive impairment and depressive symptoms scales scores, we corrected the analysis for the known variables of putamen SBR, age and years of education. The gait index variable was not normally distributed; therefore, we were unable to carry out a corrected GLM as for the other scales ratings.

CONCLUSION
In this study, we have demonstrated a high frequency of early caudate dopaminergic dysfunction in patients with recently diagnosed PD. Furthermore, our findings suggest that caudate quantification of DAT availability shortly after diagnosis may have an important role in identifying patients at risk of clinical progression to cognitive impairment, depression and gait problems in the near future. In fact, early bilateral $^{123}$I-FP-CIT caudate uptake below $-2$ SDs of the controls’ mean may be a valid indicator of more rapid onset of such symptoms. This approach might allow...
better prediction of disease course for patients with early PD and could also provide the potential to stratify cases for early targeted disease-modifying therapies.

Acknowledgements We thank John Seibyl, Heather Ovens and the Neuroimaging team at InveVO, a Konica Minolta Company (New Haven, Connecticut) for their valuable support in the Imaging analysis. Data used in the preparation of this article were obtained from the Parkinson’s Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/), for up to date information on the study, visit https://www.ppmi-info.org.

Contributors Study conception and design: JP, RD, NP. Data analysis organisation and execution: JP, RD, NP. Writing of the manuscript: JP, RD, LV, MGS, LR, DJB, DB, NP. Critical revision of the manuscript: LR, DJB, DB, NP.

Funding No funding was provided for the analysis reported in this study. The Parkinson’s Progression Markers Initiative—a public–private partnership—is funded by the Michael J. Fox Foundation for Parkinson’s Research and funding partners including AbbVie, Allergan, Axon, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali Therapeutics, GE Healthcare, Genentech, GlaxoSmithKline, Lilly, Lundbeck, Merck, Mesoscale Discovery, Pfizer, Piramal, Prevail Therapeutics, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, Voyager Therapeutics and Gobul Capital.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval All participating PPMI sites received approval from an ethical standards committee prior to study initiation and written informed consent for research was obtained from all participants in the study.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) licence, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

REFERENCES